Portage Biotech Inc. Common Stock
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PRTG Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of PRTG by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by PRTG's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to PRTG
Recent picks made for PRTG stock on CNBC
ETFs with the largest estimated holdings in PRTG
Flights by private jets registered to PRTG